Catalina Capital Group LLC Has $548,000 Position in Boston Scientific Co. (NYSE:BSX)

Catalina Capital Group LLC boosted its position in shares of Boston Scientific Co. (NYSE:BSX) by 4.0% during the 4th quarter, Holdings Channel reports. The institutional investor owned 6,140 shares of the medical equipment provider’s stock after purchasing an additional 236 shares during the quarter. Catalina Capital Group LLC’s holdings in Boston Scientific were worth $548,000 at the end of the most recent quarter.

A number of other hedge funds have also recently bought and sold shares of BSX. Quarry LP bought a new position in Boston Scientific in the second quarter valued at about $33,000. Czech National Bank lifted its position in Boston Scientific by 7.1% during the 3rd quarter. Czech National Bank now owns 299,989 shares of the medical equipment provider’s stock valued at $25,139,000 after purchasing an additional 19,833 shares during the period. GAMMA Investing LLC boosted its stake in shares of Boston Scientific by 39.9% in the 3rd quarter. GAMMA Investing LLC now owns 17,432 shares of the medical equipment provider’s stock valued at $1,461,000 after purchasing an additional 4,972 shares during the last quarter. Miracle Mile Advisors LLC grew its position in shares of Boston Scientific by 4.0% during the 3rd quarter. Miracle Mile Advisors LLC now owns 5,252 shares of the medical equipment provider’s stock worth $440,000 after buying an additional 203 shares during the period. Finally, Bank of New Hampshire raised its stake in shares of Boston Scientific by 52.6% during the third quarter. Bank of New Hampshire now owns 2,235 shares of the medical equipment provider’s stock worth $187,000 after buying an additional 770 shares during the last quarter. 89.07% of the stock is currently owned by institutional investors.

Insider Transactions at Boston Scientific

In other news, EVP John Bradley Sorenson sold 4,119 shares of the stock in a transaction that occurred on Thursday, January 2nd. The stock was sold at an average price of $90.02, for a total value of $370,792.38. Following the completion of the sale, the executive vice president now owns 35,319 shares of the company’s stock, valued at approximately $3,179,416.38. This represents a 10.44 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, EVP Arthur C. Butcher sold 14,010 shares of the firm’s stock in a transaction on Monday, November 25th. The shares were sold at an average price of $89.27, for a total transaction of $1,250,672.70. Following the completion of the transaction, the executive vice president now directly owns 978 shares of the company’s stock, valued at $87,306.06. This represents a 93.47 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 29,989 shares of company stock worth $2,702,261 in the last three months. Insiders own 0.50% of the company’s stock.

Analyst Ratings Changes

BSX has been the subject of a number of analyst reports. Deutsche Bank Aktiengesellschaft raised shares of Boston Scientific from a “hold” rating to a “buy” rating and set a $108.00 target price for the company in a report on Friday, January 10th. Morgan Stanley upped their price objective on Boston Scientific from $92.00 to $100.00 and gave the company an “overweight” rating in a report on Thursday, October 24th. Royal Bank of Canada raised their target price on Boston Scientific from $95.00 to $98.00 and gave the stock an “outperform” rating in a report on Thursday, October 24th. Truist Financial boosted their target price on Boston Scientific from $100.00 to $110.00 and gave the stock a “buy” rating in a research report on Wednesday, December 18th. Finally, StockNews.com raised shares of Boston Scientific from a “hold” rating to a “buy” rating in a research note on Wednesday, January 29th. One research analyst has rated the stock with a hold rating, twenty-one have issued a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, Boston Scientific has an average rating of “Buy” and a consensus price target of $99.73.

Boston Scientific Stock Performance

Shares of BSX opened at $102.40 on Monday. The stock has a market capitalization of $150.92 billion, a price-to-earnings ratio of 84.63, a PEG ratio of 2.68 and a beta of 0.80. Boston Scientific Co. has a 12 month low of $62.63 and a 12 month high of $104.25. The firm has a fifty day simple moving average of $93.47 and a 200 day simple moving average of $86.27. The company has a current ratio of 1.48, a quick ratio of 1.02 and a debt-to-equity ratio of 0.44.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.